The same technology has been also utilized to characterize KRAS mutants in NSCLC cells [76], and also to compare two metabolomes (plasma and serum) of small-cell lung cancer (SCLC) patients undergoing treatment with standard chemotherapy [77], as well as to detect the metabolic alteration in the serum of NSCLS patients identifying several perturbed pathways such phenylalanine metabolism, linoleic acid metabolism, and biosynthesis of bile acids [78]. This evidence concerns the gene KRAS and small cell lung carcinoma.